Genprex, Inc. enters its Q1 2026 earnings print — released today after market — with short sellers having aggressively rebuilt positions over the past month, the stock already 28% lower, and a deeply oversold tape that tells a story of sustained distribution.
The short-side pressure here is the defining feature of this week's setup. ORTEX's daily estimate puts short interest at 73.8% of the company's free float, more than doubling from roughly 34% a month ago as measured against the same free float base. Over the past week alone, the short position grew 10% in share terms, reaching approximately 1.2 million shares. That pace of accumulation into a declining stock — down 6.2% on the week and 28% over the past month to $0.83 — points to conviction rather than noise. Cost to borrow has eased somewhat, running at 17% annualised versus a peak above 21% in early April, and availability remains at around 67% of the estimated short interest — neither extremely tight nor loose, suggesting the borrow market has digested the new short demand without strain. The ORTEX short score holds at 72.4 out of 100, near a two-week high, consistent with a stock where short-side pressure is elevated and sustained.
The fundamental picture provides context for the bearish positioning. Genprex is a pre-revenue gene therapy developer, and the valuation data reflects that: the enterprise value is negative, meaning cash on hand exceeds the market capitalisation of roughly $8.6 million. On April 30, the company received a patent grant from the Israel Patent Office covering its Reqorsa gene therapy in combination with PD-1 antibodies for cancer treatment — a positive pipeline development that, so far, has not translated into price support. Q1 EPS came in at $(0.64), a meaningful improvement from $(13.00) a year ago, though the prior-year figure likely reflects reverse-split distortions rather than a genuine operational improvement. No analyst coverage exists in the current data, so there is no Street consensus to weigh against the short-side view. The RSI of 25.7 marks territory that in broader markets signals oversold conditions, though for a micro-cap with no revenue such technical signals carry limited weight on their own.
Insider activity reinforces the cautious read. The CFO and chief-level officer both sold shares in late February at $2.00 — a price the stock has since broken well below — with a combined disposal of around 16,500 shares for approximately $33,000. An independent director added two small token sells in April. None of the trades were large in dollar terms, all scoring a significance of 1 out of 10, but the consistent directional pattern of executives reducing exposure at prices above the current level is worth noting. The largest disclosed institutional holders — Lincoln Park Capital, Mayflower Financial, and Manchester Financial — collectively hold under 1% of shares, underscoring how thin the institutional ownership base is for a company of this size.
The earnings history adds a final layer. The four most recent events produced an average next-day move of roughly -2% to +7%, but five-day outcomes have been uniformly negative — averaging around -17% across all four episodes. The most severe five-day move was -27.5%, following the November 2025 release. Today's Q1 print, showing EPS improvement year-on-year, lands into a stock already deeply discounted, and the key question coming out of the release is whether management commentary on the Reqorsa pipeline and cash runway does enough to close the gap between a positive patent narrative and a short book that has been steadily growing for six weeks.
See the live data behind this article on ORTEX.
Open GNPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
